Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
US7091183B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 3, 1997 |
| Grant date | Aug 15, 2006 |
| Priority date | — |
| Expiry date | Dec 3, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7–30 of the sequence of GIP. In another embodiment, this invention provides a method of preventing and treating obesity and non-insulin dependent diabetes mellitus (Type II) in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP). In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.